var data={"title":"Diagnostic approach to hypercalcemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Diagnostic approach to hypercalcemia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/contributors\" class=\"contributor contributor_credentials\">Elizabeth Shane, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/contributors\" class=\"contributor contributor_credentials\">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/contributors\" class=\"contributor contributor_credentials\">Jean E Mulder, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 01, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypercalcemia is a relatively common clinical problem. Among all causes of hypercalcemia, primary hyperparathyroidism and malignancy are the most common, accounting for greater than 90 percent of cases [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Therefore, the diagnostic approach to hypercalcemia typically involves distinguishing between the two.</p><p>It is usually not difficult to differentiate between them. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy usually have higher calcium concentrations and are more symptomatic from hypercalcemia than individuals with primary hyperparathyroidism. Although hypercalcemia in otherwise healthy outpatients is usually due to primary hyperparathyroidism and malignancy is more often responsible for hypercalcemia in hospitalized patients, other potential causes of hypercalcemia must be considered (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>).</p><p>This topic will review the diagnostic approach to hypercalcemia. The clinical manifestations, etiology, and treatment are reviewed separately. (See <a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">&quot;Clinical manifestations of hypercalcemia&quot;</a> and <a href=\"topic.htm?path=etiology-of-hypercalcemia\" class=\"medical medical_review\">&quot;Etiology of hypercalcemia&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CONFIRM HYPERCALCEMIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The first step in the evaluation of a patient with hypercalcemia is to verify with repeat measurement (total calcium corrected for albumin) that there is a true increase in the serum calcium concentration. If available, previous values for serum calcium should also be reviewed. The presence of longstanding asymptomatic hypercalcemia is more suggestive of primary hyperparathyroidism and also raises the much less common possibility of familial hypocalciuric hypercalcemia.</p><p>The degree of hypercalcemia also may be useful diagnostically. Primary hyperparathyroidism is often associated with borderline or mild hypercalcemia (serum calcium concentration often below 11 <span class=\"nowrap\">mg/dL</span> [2.75 <span class=\"nowrap\">mmol/L])</span>. Values above 13 <span class=\"nowrap\">mg/dL</span> (3.25 <span class=\"nowrap\">mmol/L)</span> are unusual in primary hyperparathyroidism, although they do occur and are more common in patients with malignancy-associated hypercalcemia. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;</a> and <a href=\"topic.htm?path=disorders-of-the-calcium-sensing-receptor-familial-hypocalciuric-hypercalcemia-and-autosomal-dominant-hypocalcemia\" class=\"medical medical_review\">&quot;Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia&quot;</a> and <a href=\"topic.htm?path=hypercalcemia-of-malignancy-mechanisms\" class=\"medical medical_review\">&quot;Hypercalcemia of malignancy: Mechanisms&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H953983337\"><span class=\"h2\">Albumin-calcium correction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In almost all patients, hypercalcemia is due to an elevation in the physiologically important ionized (or free) calcium concentration. However, 40 to 45 percent of the calcium in serum is bound to protein, principally albumin. As a result, the total serum calcium concentration in patients with low or high serum albumin levels may not accurately reflect the physiologically important ionized (or free) calcium concentration. Increased protein binding can cause an elevation in the serum total calcium concentration without any rise in the serum ionized calcium concentration.</p><p>Patients in whom this can occur include those with hyperalbuminemia due to severe dehydration and rare patients with multiple myeloma who have a calcium-binding paraprotein. This phenomenon is called pseudohypercalcemia (or factitious hypercalcemia) since the patient has a normal ionized serum calcium concentration. Alternatively, in patients with hypoalbuminemia due to chronic illness or malnutrition, total serum calcium concentration may be normal when serum ionized calcium is elevated.</p><p>Thus, in patients with hypo- or hyperalbuminemia, the measured calcium concentration should be corrected for the abnormality in albumin (<a href=\"topic.htm?path=calculator-calcium-correction-in-hypoalbuminemia\" class=\"calc calc_professional\">calculator 1</a>) or for standard units (<a href=\"topic.htm?path=calculator-calcium-correction-in-hypoalbuminemia-si-units\" class=\"calc calc_professional\">calculator 2</a>). If a laboratory known to measure ionized calcium reliably is available, some authorities prefer to measure the serum ionized calcium in this situation. (See <a href=\"topic.htm?path=relation-between-total-and-ionized-serum-calcium-concentrations\" class=\"medical medical_review\">&quot;Relation between total and ionized serum calcium concentrations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4227158633\"><span class=\"h1\">DETERMINING THE ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypercalcemia has many causes (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>). The etiology may be obvious from the patient's history and physical examination. When the cause is not obvious or a suspected cause needs to be confirmed, other biochemical tests are indicated.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Clinical clues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the signs and symptoms of hypercalcemia are similar regardless of the etiology, there are several features of the clinical evaluation that may help to differentiate the etiology of hypercalcemia. Clinical findings that favor the diagnosis of primary hyperparathyroidism include an asymptomatic patient with chronic hypercalcemia, a postmenopausal woman, a normal physical examination, no other obvious cause of hypercalcemia (such as sarcoidosis), a family history of hyperparathyroidism, and evidence of multiple endocrine neoplasia. (See <a href=\"topic.htm?path=classification-and-genetics-of-multiple-endocrine-neoplasia-type-2\" class=\"medical medical_review\">&quot;Classification and genetics of multiple endocrine neoplasia type 2&quot;</a> and <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-definition-and-genetics\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Definition and genetics&quot;</a>.)</p><p>Patients with hypercalcemia of malignancy often have higher concentrations of, and more rapid increases in, serum calcium and subsequently are more symptomatic (<a href=\"image.htm?imageKey=ENDO%2F54647\" class=\"graphic graphic_table graphicRef54647 \">table 2</a>) (see <a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">&quot;Clinical manifestations of hypercalcemia&quot;</a>). In addition, patients with this disorder typically have advanced disease and a poor prognosis.</p><p>A review of diet and medications (prescription and nonprescription drugs, herbal preparations, calcium and vitamin supplements) is important to assess for the milk-alkali syndrome and drug-induced hypercalcemia (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>) (see <a href=\"topic.htm?path=etiology-of-hypercalcemia#H13\" class=\"medical medical_review\">&quot;Etiology of hypercalcemia&quot;, section on 'Miscellaneous causes'</a> and <a href=\"topic.htm?path=the-milk-alkali-syndrome\" class=\"medical medical_review\">&quot;The milk-alkali syndrome&quot;</a>). If possible, any medication that may be causing hypercalcemia should be discontinued. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation#H8\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;, section on 'Drugs'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Laboratory evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial goal of the laboratory evaluation is to differentiate parathyroid hormone (PTH)-mediated hypercalcemia (primary hyperparathyroidism and familial hyperparathyroid syndromes) from non-PTH mediated hypercalcemia (primarily malignancy, vitamin D intoxication, granulomatous disease) (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>). Thus, once hypercalcemia is confirmed, the next step is measurement of serum PTH (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>). (See <a href=\"topic.htm?path=parathyroid-hormone-assays-and-their-clinical-use\" class=\"medical medical_review\">&quot;Parathyroid hormone assays and their clinical use&quot;</a>.)</p><p>There appears to be a higher incidence of primary hyperparathyroidism in patients with malignancy than in the general population [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Thus, despite the increased cost, it is reasonable to order an intact PTH assay as part of the routine evaluation for hypercalcemia even in a patient with known malignant disease. (See <a href=\"topic.htm?path=hypercalcemia-of-malignancy-mechanisms#H9\" class=\"medical medical_review\">&quot;Hypercalcemia of malignancy: Mechanisms&quot;, section on 'Coexisting primary hyperparathyroidism'</a> and <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation#H6\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;, section on 'Malignancy'</a>.)</p><p class=\"headingAnchor\" id=\"H3418116001\"><span class=\"h3\">Elevated parathyroid hormone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A frankly elevated PTH concentration in the setting of hypercalcemia is likely the result of primary hyperparathyroidism (<a href=\"image.htm?imageKey=ENDO%2F50252\" class=\"graphic graphic_figure graphicRef50252 \">figure 1</a> and <a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Additional evaluation in such patients to determine management is reviewed separately. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3791999050\"><span class=\"h3\">Mid- to upper-normal or minimally elevated parathyroid hormone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ten to 20 percent of patients with primary hyperparathyroidism have a serum PTH concentration in the upper end of the normal range; such a &quot;normal&quot; level (ie, not suppressed but not frankly elevated) is also virtually diagnostic of primary hyperparathyroidism since it is still inappropriately high considering the presence of hypercalcemia [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/5\" class=\"abstract_t\">5</a>]. However, in this circumstance, the diagnosis of familial hypocalciuric hypercalcemia also should be considered, and urinary calcium excretion (24-hour urinary calcium or calcium-to-creatinine ratio) should be measured (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>). (See <a href=\"#H8\" class=\"local\">'Other tests'</a> below and <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation#H3564970\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;, section on '24-hour urinary calcium'</a>.)</p><p class=\"headingAnchor\" id=\"H3446399644\"><span class=\"h3\">Low-normal or low parathyroid hormone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A low or low-normal serum intact PTH level (below 20 <span class=\"nowrap\">pg/mL)</span> is most consistent with non-PTH-mediated hypercalcemia (<a href=\"image.htm?imageKey=ENDO%2F50252\" class=\"graphic graphic_figure graphicRef50252 \">figure 1</a> and <a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>). While it is unusual for a patient with proven primary hyperparathyroidism to have a serum PTH concentration in the lower half of the normal range, it may occur. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation#H4\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;, section on 'Serum PTH'</a>.)</p><p>In the presence of low serum PTH concentrations (&lt;20 <span class=\"nowrap\">pg/mL),</span> PTH-related protein (PTHrp) and vitamin D metabolites should be measured to assess for hypercalcemia of malignancy and vitamin D intoxication (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>). If PTHrp and vitamin D metabolites are also low, another source for the hypercalcemia must be considered (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>).</p><p>Additional laboratory data (including serum protein electrophoresis [SPEP] for possible multiple myeloma, thyroid-stimulating hormone [TSH], <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a>) will often lead to the correct diagnosis (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h4\">PTH-related protein</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Humoral hypercalcemia of malignancy is one of the most common causes of non-parathyroid hormone (PTH)-mediated hypercalcemia. It should be particularly suspected if there is clinical evidence of malignancy, usually a solid tumor, and the hypercalcemia is of relatively recent onset. Thus, if the patient has longstanding hypercalcemia and a low serum PTH, one should consider one of the other non-PTH-mediated disorders rather than a malignancy (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a> and <a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>).</p><p>The diagnosis of humoral hypercalcemia of malignancy can be confirmed by demonstrating an elevated serum concentration of PTHrp [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/3\" class=\"abstract_t\">3</a>], which is the primary mediator of hypercalcemia in most cases [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/6\" class=\"abstract_t\">6</a>]. However, this assay is usually not necessary for diagnosis, since most patients have clinically apparent malignancy. Levels of PTH and 1,25-dihydroxyvitamin D (calcitriol) are usually appropriately suppressed in these patients [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/3,7,8\" class=\"abstract_t\">3,7,8</a>].</p><p>PTHrp is reviewed in more detail elsewhere. (See <a href=\"topic.htm?path=hypercalcemia-of-malignancy-mechanisms#H1048261776\" class=\"medical medical_review\">&quot;Hypercalcemia of malignancy: Mechanisms&quot;, section on 'PTH-related protein'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h4\">Vitamin D metabolites</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum concentrations of the vitamin D metabolites, 25-hydroxyvitamin D (25[OH]D, calcidiol) and 1,25-dihydroxyvitamin D (calcitriol), should be measured if there is no obvious malignancy and PTH is not elevated [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An elevated serum concentration of 25(OH)D is indicative of vitamin D intoxication due to the ingestion of either vitamin D or calcidiol itself [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Although the serum concentration of 25(OH)D at which hypercalcemia typically occurs is undefined, many experts define vitamin D intoxication as a value &gt;150 <span class=\"nowrap\">ng/mL</span> (374 <span class=\"nowrap\">nmol/L)</span> [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/11\" class=\"abstract_t\">11</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the other hand, increased levels of 1,25-dihydroxyvitamin D may be induced by direct intake of this metabolite, extrarenal production in granulomatous diseases or lymphoma, or increased renal production that can be induced by primary hyperparathyroidism but not by PTHrp [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=hypercalcemia-in-granulomatous-diseases\" class=\"medical medical_review\">&quot;Hypercalcemia in granulomatous diseases&quot;</a>.)</p><p/><p>In patients with elevated 1,25-dihydroxyvitamin D, chest radiograph (looking for malignancy or sarcoidosis) may be helpful. Patients with granulomatous disease or lymphoma generally have widespread pulmonary and extrapulmonary disease. In the absence of such involvement, a systematic search for occult pulmonary, renal, hepatic, ocular, and bone marrow granulomas is indicated when no other cause for increased 1,25-dihydroxyvitamin D is apparent.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h4\">Other tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of low serum levels of PTH, PTHrp, and low or normal vitamin D metabolites suggests some other source for the hypercalcemia. In the absence of malignancy or increased PTHrp, unsuspected stimulation of bone resorption (as with multiple myeloma, thyrotoxicosis, immobilization, or <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a> toxicity) and unrecognized calcium intake in the face of renal insufficiency (as in the milk-alkali syndrome) are the most likely candidates [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/12\" class=\"abstract_t\">12</a>] (see <a href=\"topic.htm?path=etiology-of-hypercalcemia\" class=\"medical medical_review\">&quot;Etiology of hypercalcemia&quot;</a>). Additional laboratory data (including serum and urinary protein electrophoresis for possible multiple myeloma, TSH, vitamin A) will often provide the correct diagnosis.</p><p>Measurement of the serum phosphate concentration and urinary calcium excretion also may be helpful in selected cases. Hyperparathyroidism and humoral hypercalcemia of malignancy (due to PTHrp) may be associated with frank hypophosphatemia or low-normal serum phosphate levels resulting from inhibition of renal proximal tubular phosphate reabsorption. In comparison, the serum phosphate concentration is normal or elevated in granulomatous diseases, vitamin D intoxication, immobilization, thyrotoxicosis, milk-alkali syndrome, and metastatic bone disease. The serum phosphate concentration is variable in familial hypocalciuric hypercalcemia.</p><p>Urinary calcium excretion is usually raised or high-normal in hyperparathyroidism and hypercalcemia of malignancy. In contrast, there are three disorders in which an increase in renal calcium reabsorption leads to relative hypocalciuria (less than 100 <span class=\"nowrap\">mg/day</span> [2.5 <span class=\"nowrap\">mmol/day]):</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The milk-alkali syndrome in which the associated metabolic alkalosis enhances calcium reabsorption via an uncertain mechanism [<a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=the-milk-alkali-syndrome\" class=\"medical medical_review\">&quot;The milk-alkali syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thiazide diuretics, which directly enhance active calcium reabsorption in the distal tubule. (See <a href=\"topic.htm?path=diuretics-and-calcium-balance\" class=\"medical medical_review\">&quot;Diuretics and calcium balance&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial hypocalciuric hypercalcemia in which the fractional excretion of calcium is often less than 1 percent. Two other clues to the possible presence of this disorder are a family history of hypercalcemia and few (if any) hypercalcemic symptoms. (See <a href=\"topic.htm?path=disorders-of-the-calcium-sensing-receptor-familial-hypocalciuric-hypercalcemia-and-autosomal-dominant-hypocalcemia\" class=\"medical medical_review\">&quot;Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia&quot;</a>.)</p><p/><p>Other tests that may also be helpful in selected cases are the serum chloride concentration and bone radiographs. A serum chloride concentration above 103 <span class=\"nowrap\">mEq/L</span> (associated with a mild fall in the serum bicarbonate concentration) is consistent with primary hyperparathyroidism, while a lower serum chloride concentration and metabolic alkalosis are characteristic of the milk-alkali syndrome. Evidence of osteitis fibrosa on bone films is very specific for primary hyperparathyroidism but is only seen in approximately 5 percent of cases.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">AFTER DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment for hypercalcemia should be aimed at lowering the serum calcium concentration and, if possible, correcting or decreasing the underlying disease. Effective treatments are discussed separately. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;</a> and <a href=\"topic.htm?path=primary-hyperparathyroidism-management\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Management&quot;</a> and <a href=\"topic.htm?path=hypercalcemia-in-granulomatous-diseases\" class=\"medical medical_review\">&quot;Hypercalcemia in granulomatous diseases&quot;</a> and <a href=\"topic.htm?path=disorders-of-the-calcium-sensing-receptor-familial-hypocalciuric-hypercalcemia-and-autosomal-dominant-hypocalcemia\" class=\"medical medical_review\">&quot;Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnostic approach to hypercalcemia typically involves clinical evaluation and laboratory testing to distinguish between primary hyperparathyroidism and malignancy, which together account for greater than 90 percent of cases. The remaining 10 percent of patients with hypercalcemia may have one of many causes (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a>) that must be systematically considered and evaluated (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum calcium should be corrected for albumin, and an elevated concentration should be confirmed by repeat sampling. (See <a href=\"#H2\" class=\"local\">'Confirm hypercalcemia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical evaluation, including duration of hypercalcemia, presence or absence of symptoms, family history, and medications, may help determine the etiology of hypercalcemia. (See <a href=\"#H3\" class=\"local\">'Clinical clues'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measurement of intact parathyroid hormone (PTH) is important to distinguish PTH-mediated from non-PTH-mediated causes of hypercalcemia. A frankly elevated PTH concentration or a PTH value in the upper half of the normal range in the setting of hypercalcemia is likely the result of primary hyperparathyroidism. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PTH concentrations below 20 <span class=\"nowrap\">pg/mL</span> in the setting of hypercalcemia are usually not consistent with primary hyperparathyroidism and indicate the need for evaluation for other causes of hypercalcemia (<a href=\"image.htm?imageKey=ENDO%2F66865\" class=\"graphic graphic_table graphicRef66865 \">table 1</a> and <a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>). This evaluation should include measurement of PTH-related protein (PTHrp) and vitamin D metabolites. (See <a href=\"#H6\" class=\"local\">'PTH-related protein'</a> above and <a href=\"#H7\" class=\"local\">'Vitamin D metabolites'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the diagnosis is still not clear, other tests should be considered, including thyroid-stimulating hormone (TSH), serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a>. (See <a href=\"#H8\" class=\"local\">'Other tests'</a> above.)</p><p/><p>The treatment of hypercalcemia is reviewed separately. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/1\" class=\"nounderline abstract_t\">Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res 1991; 6 Suppl 2:S51.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/2\" class=\"nounderline abstract_t\">Burtis WJ, Wu TL, Insogna KL, Stewart AF. Humoral hypercalcemia of malignancy. Ann Intern Med 1988; 108:454.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/3\" class=\"nounderline abstract_t\">Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/4\" class=\"nounderline abstract_t\">Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/5\" class=\"nounderline abstract_t\">Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991; 37:162.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/6\" class=\"nounderline abstract_t\">Rosol TJ, Capen CC. Mechanisms of cancer-induced hypercalcemia. Lab Invest 1992; 67:680.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/7\" class=\"nounderline abstract_t\">Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/8\" class=\"nounderline abstract_t\">Kremer R, Shustik C, Tabak T, et al. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med 1996; 100:406.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/9\" class=\"nounderline abstract_t\">Kimball S, Vieth R. Self-prescribed high-dose vitamin D3: effects on biochemical parameters in two men. Ann Clin Biochem 2008; 45:106.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/10\" class=\"nounderline abstract_t\">Jacobus CH, Holick MF, Shao Q, et al. Hypervitaminosis D associated with drinking milk. N Engl J Med 1992; 326:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/11\" class=\"nounderline abstract_t\">Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.</a></li><li><a href=\"https://www.uptodate.com/contents/diagnostic-approach-to-hypercalcemia/abstract/12\" class=\"nounderline abstract_t\">Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995; 74:89.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 836 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CONFIRM HYPERCALCEMIA</a><ul><li><a href=\"#H953983337\" id=\"outline-link-H953983337\">Albumin-calcium correction</a></li></ul></li><li><a href=\"#H4227158633\" id=\"outline-link-H4227158633\">DETERMINING THE ETIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Clinical clues</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Laboratory evaluation</a><ul><li><a href=\"#H3418116001\" id=\"outline-link-H3418116001\">- Elevated parathyroid hormone</a></li><li><a href=\"#H3791999050\" id=\"outline-link-H3791999050\">- Mid- to upper-normal or minimally elevated parathyroid hormone</a></li><li><a href=\"#H3446399644\" id=\"outline-link-H3446399644\">- Low-normal or low parathyroid hormone</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">PTH-related protein</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Vitamin D metabolites</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Other tests</a></li></ul></li></ul></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">AFTER DIAGNOSIS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/836|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51698\" class=\"graphic graphic_algorithm\">- Diagnostic approach to hypercalcemia</a></li></ul></li><li><div id=\"ENDO/836|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/50252\" class=\"graphic graphic_figure\">- PTH and calcium</a></li></ul></li><li><div id=\"ENDO/836|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/66865\" class=\"graphic graphic_table\">- Causes of hypercalcemia</a></li><li><a href=\"image.htm?imageKey=ENDO/54647\" class=\"graphic graphic_table\">- Clinical manifestations of hypercalcemia</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-calcium-correction-in-hypoalbuminemia\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Calcium correction in hypoalbuminemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-calcium-correction-in-hypoalbuminemia-si-units\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Calcium correction in hypoalbuminemia (SI units)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=classification-and-genetics-of-multiple-endocrine-neoplasia-type-2\" class=\"medical medical_review\">Classification and genetics of multiple endocrine neoplasia type 2</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">Clinical manifestations of hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disorders-of-the-calcium-sensing-receptor-familial-hypocalciuric-hypercalcemia-and-autosomal-dominant-hypocalcemia\" class=\"medical medical_review\">Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diuretics-and-calcium-balance\" class=\"medical medical_review\">Diuretics and calcium balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-of-hypercalcemia\" class=\"medical medical_review\">Etiology of hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypercalcemia-in-granulomatous-diseases\" class=\"medical medical_review\">Hypercalcemia in granulomatous diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypercalcemia-of-malignancy-mechanisms\" class=\"medical medical_review\">Hypercalcemia of malignancy: Mechanisms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-definition-and-genetics\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Definition and genetics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=parathyroid-hormone-assays-and-their-clinical-use\" class=\"medical medical_review\">Parathyroid hormone assays and their clinical use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-hyperparathyroidism-management\" class=\"medical medical_review\">Primary hyperparathyroidism: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=relation-between-total-and-ionized-serum-calcium-concentrations\" class=\"medical medical_review\">Relation between total and ionized serum calcium concentrations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-milk-alkali-syndrome\" class=\"medical medical_review\">The milk-alkali syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">Treatment of hypercalcemia</a></li></ul></div></div>","javascript":null}